{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T01:03:52Z","timestamp":1784077432645,"version":"3.55.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T00:00:00Z","timestamp":1779321600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:00:00Z","timestamp":1784073600000},"content-version":"vor","delay-in-days":55,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"DOI":"10.1007\/s12672-026-05202-x","type":"journal-article","created":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T18:24:18Z","timestamp":1779387858000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Nivolumab and ipilimumab combination therapy for melanoma efficacy, safety and clinical integration in metastatic and adjuvant settings"],"prefix":"10.1007","volume":"17","author":[{"given":"Rechner","family":"Afuh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Ashinze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suvam","family":"Banerjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Egbunu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew Olamide","family":"Olaniyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayodele Blessing","family":"Ayo-ige","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eniola Kabirat","family":"Soyinka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad Olawale","family":"Atere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Igwe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yetunde Morayo","family":"Oladipupo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayomide","family":"Obaoye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yisa","family":"Nasiru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caleb","family":"Aboderin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Olowookere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,21]]},"reference":[{"issue":"4","key":"5202_CR1","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1615\/CritRevEukaryotGeneExpr.2020028454","volume":"30","author":"B Ahmed","year":"2020","unstructured":"Ahmed B, Qadir MI, Ghafoor S. Malignant melanoma: Skin cancer-diagnosis, prevention, and treatment. Crit Rev Eukaryot Gene Expr. 2020;30(4):291\u20137. https:\/\/doi.org\/10.1615\/CritRevEukaryotGeneExpr.2020028454.","journal-title":"Crit Rev Eukaryot Gene Expr"},{"issue":"3","key":"5202_CR2","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363. https:\/\/doi.org\/10.3322\/caac.21834.","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"5202_CR3","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1007\/s40257-022-00681-4","volume":"23","author":"F Aroldi","year":"2022","unstructured":"Aroldi F, Middleton MR. Long-term outcomes of immune checkpoint inhibition in metastatic melanoma. Am J Clin Dermatol. 2022;23(3):331\u20138. https:\/\/doi.org\/10.1007\/s40257-022-00681-4.","journal-title":"Am J Clin Dermatol"},{"issue":"3","key":"5202_CR4","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1007\/s10555-021-09976-0","volume":"40","author":"MZ Wojtukiewicz","year":"2021","unstructured":"Wojtukiewicz MZ, Rek MM, Karpowicz K, et al. Inhibitors of immune checkpoints-PD-1, PD-L1, CTLA-4-new opportunities for cancer patients and a new challenge for internists and general practitioners. Cancer Metastasis Rev. 2021;40(3):949\u201382. https:\/\/doi.org\/10.1007\/s10555-021-09976-0.","journal-title":"Cancer Metastasis Rev"},{"issue":"10\u201312","key":"5202_CR5","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1080\/15384047.2015.1095401","volume":"22","author":"T Hughes","year":"2021","unstructured":"Hughes T, Klairmont M, Sharfman WH, Kaufman HL. Interleukin-2, Ipilimumab, and Anti-PD-1: clinical management and the evolving role of immunotherapy for the treatment of patients with metastatic melanoma. Cancer Biol Ther. 2021;22(10\u201312):513\u201326. https:\/\/doi.org\/10.1080\/15384047.2015.1095401.","journal-title":"Cancer Biol Ther"},{"key":"5202_CR6","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2024.1403021","volume":"11","author":"C Sorino","year":"2024","unstructured":"Sorino C, Iezzi S, Ciuffreda L, Falcone I. Immunotherapy in melanoma: advances, pitfalls, and future perspectives. Front Mol Biosci. 2024;11:1403021. https:\/\/doi.org\/10.3389\/fmolb.2024.1403021.","journal-title":"Front Mol Biosci"},{"issue":"12","key":"5202_CR7","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21124427","volume":"21","author":"O Kooshkaki","year":"2020","unstructured":"Kooshkaki O, Derakhshani A, Hosseinkhani N, et al. Combination of Ipilimumab and Nivolumab in cancers: From clinical practice to ongoing clinical trials. Int J Mol Sci. 2020;21(12):4427. https:\/\/doi.org\/10.3390\/ijms21124427.","journal-title":"Int J Mol Sci"},{"key":"5202_CR8","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-009061","volume":"12","author":"AK Maloney","year":"2024","unstructured":"Maloney AK, Giobbie-Hurder A, Katukota N, Fogarasi MC, Ott PA, Hodi FS, et al. Nivolumab maintenance improves overall survival of patients with advanced melanoma who experience severe immune-related adverse events on nivolumab plus ipilimumab. J Immunother Cancer. 2024;12:e009061. https:\/\/doi.org\/10.1136\/jitc-2024-009061.","journal-title":"J Immunother Cancer"},{"issue":"1","key":"5202_CR9","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1056\/NEJMoa1504030","volume":"373","author":"J Larkin","year":"2015","unstructured":"Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined Nivolumab and Ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373(1):23\u201334. https:\/\/doi.org\/10.1056\/NEJMoa1504030.","journal-title":"N Engl J Med"},{"issue":"17","key":"5202_CR10","doi-asserted-by":"publisher","first-page":"5191","DOI":"10.1158\/1078-0432.CCR-18-1550","volume":"25","author":"SA Weiss","year":"2019","unstructured":"Weiss SA, Wolchok JD, Sznol M. Immunotherapy of melanoma: facts and hopes. Clin Cancer Res. 2019;25(17):5191\u2013201. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-1550.","journal-title":"Clin Cancer Res"},{"key":"5202_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2024.216633","volume":"586","author":"J Zhang","year":"2024","unstructured":"Zhang J, Joshua AM, Li Y, O\u2019Meara CH, Morris MJ, Khachigian LM. Targeted therapy, immunotherapy, and small molecules and peptidomimetics as emerging immunoregulatory agents for melanoma. Cancer Lett. 2024;586:216633. https:\/\/doi.org\/10.1016\/j.canlet.2024.216633.","journal-title":"Cancer Lett"},{"issue":"3","key":"5202_CR12","doi-asserted-by":"publisher","first-page":"410","DOI":"10.7150\/jca.17144","volume":"8","author":"L Guo","year":"2017","unstructured":"Guo L, Zhang H, Chen B. Nivolumab as Programmed Death-1 (PD-1) inhibitor for targeted immunotherapy in tumor. J Cancer. 2017;8(3):410\u20136. https:\/\/doi.org\/10.7150\/jca.17144.","journal-title":"J Cancer"},{"issue":"2","key":"5202_CR13","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1177\/1758834014567469","volume":"7","author":"DB Johnson","year":"2015","unstructured":"Johnson DB, Peng C, Sosman JA. Nivolumab in melanoma: latest evidence and clinical potential. Ther Adv Med Oncol. 2015;7(2):97\u2013106. https:\/\/doi.org\/10.1177\/1758834014567469.","journal-title":"Ther Adv Med Oncol"},{"issue":"12","key":"5202_CR14","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1016\/j.annonc.2024.08.2330","volume":"35","author":"GV Long","year":"2024","unstructured":"Long GV, Carlino MS, McNeil C, et al. Pembrolizumab versus ipilimumab for advanced melanoma: 10-year follow-up of the phase III KEYNOTE-006 study. Ann Oncol. 2024;35(12):1191\u20139. https:\/\/doi.org\/10.1016\/j.annonc.2024.08.2330.","journal-title":"Ann Oncol"},{"issue":"21","key":"5202_CR15","doi-asserted-by":"publisher","first-page":"2006","DOI":"10.1056\/NEJMoa1414428","volume":"372","author":"MA Postow","year":"2015","unstructured":"Postow MA, Chesney J, Pavlick AC, et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med. 2015;372(21):2006\u201317. https:\/\/doi.org\/10.1056\/NEJMoa1414428.","journal-title":"N Engl J Med"},{"issue":"3","key":"5202_CR16","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1097\/CMR.0000000000000816","volume":"32","author":"S Pedersen","year":"2022","unstructured":"Pedersen S, M\u00f8ller S, Donia M, Persson GF, Svane IM, Ellebaek E. Real-world data on melanoma brain metastases and survival outcome. Melanoma Res. 2022;32(3):173\u201382. https:\/\/doi.org\/10.1097\/CMR.0000000000000816.","journal-title":"Melanoma Res"},{"issue":"3","key":"5202_CR17","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1007\/s11060-022-04036-1","volume":"158","author":"A Berger","year":"2022","unstructured":"Berger A, Bernstein K, Alzate JD, et al. Significant survival improvements for patients with melanoma brain metastases: can we reach cure in the current era? J Neurooncol. 2022;158(3):471\u201380. https:\/\/doi.org\/10.1007\/s11060-022-04036-1.","journal-title":"J Neurooncol"},{"issue":"8","key":"5202_CR18","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1056\/NEJMoa1805453","volume":"379","author":"HA Tawbi","year":"2018","unstructured":"Tawbi HA, Forsyth PA, Algazi A, et al. Combined Nivolumab and Ipilimumab in melanoma metastatic to the brain. N Engl J Med. 2018;379(8):722\u201330. https:\/\/doi.org\/10.1056\/NEJMoa1805453.","journal-title":"N Engl J Med"},{"issue":"3","key":"5202_CR19","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/S1470-2045(24)00735-6","volume":"26","author":"GV Long","year":"2025","unstructured":"Long GV, Atkinson V, Lo SN, et al. Ipilimumab plus Nivolumab versus Nivolumab alone in patients with melanoma brain metastases (ABC): 7-year follow-up of a multicentre, open-label, randomised, phase 2 study. Lancet Oncol. 2025;26(3):320\u201330. https:\/\/doi.org\/10.1016\/S1470-2045(24)00735-6.","journal-title":"Lancet Oncol"},{"issue":"4","key":"5202_CR20","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/j.annonc.2023.01.004","volume":"34","author":"JM Versluis","year":"2023","unstructured":"Versluis JM, Menzies AM, Sikorska K, et al. Survival update of neoadjuvant Ipilimumab plus Nivolumab in macroscopic stage III melanoma in the OpACIN and OpACIN-neo trials. Ann Oncol. 2023;34(4):420\u201330. https:\/\/doi.org\/10.1016\/j.annonc.2023.01.004.","journal-title":"Ann Oncol"},{"key":"5202_CR21","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2402604","author":"CU Blank","year":"2024","unstructured":"Blank CU, Lucas MW, Scolyer RA, et al. Neoadjuvant nivolumab and ipilimumab in resectable stage III melanoma (NADINA). N Engl J Med. 2024. https:\/\/doi.org\/10.1056\/NEJMoa2402604.","journal-title":"N Engl J Med"},{"issue":"9","key":"5202_CR22","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1056\/NEJMoa2211437","volume":"388","author":"SP Patel","year":"2023","unstructured":"Patel SP, Othus M, Chen Y, et al. Neoadjuvant-adjuvant or adjuvant-only Pembrolizumab in advanced melanoma. N Engl J Med. 2023;388(9):813\u201323. https:\/\/doi.org\/10.1056\/NEJMoa2211437.","journal-title":"N Engl J Med"},{"key":"5202_CR23","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-22-3106","author":"J Larkin","year":"2023","unstructured":"Larkin J, Del Vecchio M, Mandal\u00e1 M, et al. Adjuvant nivolumab versus ipilimumab in resected stage III\/IV melanoma: 5-year efficacy and biomarker results from CheckMate 238. Clin Cancer Res. 2023. https:\/\/doi.org\/10.1158\/1078-0432.CCR-22-3106.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"5202_CR24","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1200\/JCO.22.00533","volume":"41","author":"JS Weber","year":"2023","unstructured":"Weber JS, Schadendorf D, Del Vecchio M, et al. Adjuvant therapy of Nivolumab combined with Ipilimumab versus Nivolumab alone in patients with resected stage IIIB-D or stage IV melanoma (CheckMate 915). J Clin Oncol. 2023;41(3):517\u201327.","journal-title":"J Clin Oncol"},{"key":"5202_CR25","unstructured":"Goodman A. Comparing Nivolumab Plus Ipilimumab vs Nivolumab Alone in Resected Stage III to IV Melanoma. The ASCO Post. https:\/\/ascopost.com\/issues\/may-10-2021\/comparing-nivolumab-plus-ipilimumab-vs-nivolumab-alone-in-resected-stage-iii-to-iv-melanoma\/#:~:text=Subscribe-,Comparing%20Nivolumab%20Plus%20Ipilimumab%20vs%20Nivolumab%20Alone%20in%20Resected%20Stage,2."},{"key":"5202_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)01654-3","author":"JMK de Filette","year":"2023","unstructured":"de Filette JMK, Lienhard M, Van de Ven A, et al. IMMUNED: adjuvant nivolumab plus ipilimumab versus nivolumab alone versus ipilimumab alone in resected stage IV melanoma. Lancet. 2023. https:\/\/doi.org\/10.1016\/S0140-6736(22)01654-3.","journal-title":"Lancet"},{"issue":"11","key":"5202_CR27","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1016\/S1470-2045(20)30494-0","volume":"21","author":"PA Ascierto","year":"2020","unstructured":"Ascierto PA, Del Vecchio M, Mandala M. Adjuvant nivolumab versus ipilimumab in resected stage IIIB\u2013C and stage IVA\u2013B melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial. Lancet Oncol. 2020;21(11):1465\u201377.","journal-title":"Lancet Oncol"},{"issue":"17","key":"5202_CR28","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","volume":"36","author":"JR Brahmer","year":"2018","unstructured":"Brahmer JR, Lacchetti C, Schneider BJ, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO clinical practice guideline. J Clin Oncol. 2018;36(17):1714\u201368.","journal-title":"J Clin Oncol"},{"key":"5202_CR29","doi-asserted-by":"publisher","DOI":"10.36849\/JDD.85411","author":"O Ginita","year":"2023","unstructured":"Ginita O, et al. Management of cutaneous immune-related adverse events in patients treated with immune checkpoint inhibitors. J Drugs Dermatol. 2023. https:\/\/doi.org\/10.36849\/JDD.85411.","journal-title":"J Drugs Dermatol"},{"issue":"9","key":"5202_CR30","doi-asserted-by":"publisher","first-page":"582","DOI":"10.6004\/jnccn.2024.0057","volume":"22","author":"JA Thompson","year":"2024","unstructured":"Thompson JA, Schneider BJ, Brahmer J, et al. NCCN guidelines insights: management of immunotherapy-related toxicities, version 2.2024. J Natl Compr Canc Netw. 2024;22(9):582\u201392.","journal-title":"J Natl Compr Canc Netw"},{"issue":"2","key":"5202_CR31","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1200\/JCO.22.01763","volume":"41","author":"MB Atkins","year":"2023","unstructured":"Atkins MB, Lee SJ, Chmielowski B, et al. Combination dabrafenib and trametinib versus combination nivolumab and ipilimumab for patients with advanced BRAF-mutant melanoma: the DREAMseq trial. J Clin Oncol. 2023;41(2):186\u201397.","journal-title":"J Clin Oncol"},{"issue":"1","key":"5202_CR32","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-023-00380-1","volume":"7","author":"RJ Verheijden","year":"2023","unstructured":"Verheijden RJ, van Eijs MJM, May AM, van Wijk F, Suijkerbuijk KPM. Immunosuppression for immune-related adverse events during checkpoint inhibition: an intricate balance. npj Precis Oncol. 2023;7(1):41. https:\/\/doi.org\/10.1038\/s41698-023-00380-1.","journal-title":"npj Precis Oncol"},{"issue":"1","key":"5202_CR33","doi-asserted-by":"publisher","DOI":"10.3390\/pathogens14010041","volume":"14","author":"N Kang","year":"2025","unstructured":"Kang N, Subramanian VS, Agrawal A. Influence of aging and immune alterations on susceptibility to pneumococcal pneumonia in the elderly. Pathogens. 2025;14(1): 41. https:\/\/doi.org\/10.3390\/pathogens14010041.","journal-title":"Pathogens"},{"key":"5202_CR34","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1020058","volume":"12","author":"R Stoff","year":"2022","unstructured":"Stoff R, Grynberg S, Asher N, et al. Efficacy and toxicity of ipilimumab-nivolumab combination therapy in elderly metastatic melanoma patients. Front Oncol. 2022;12:1020058. https:\/\/doi.org\/10.3389\/fonc.2022.1020058.","journal-title":"Front Oncol"},{"issue":"5","key":"5202_CR35","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.12327","volume":"5","author":"N Ahmed","year":"2022","unstructured":"Ahmed N, Vengalasetti Y, Haslam A, Prasad V. Association of adjuvant or metastatic setting with discontinuation of cancer drugs in clinical trials. JAMA Netw Open. 2022;5(5):e2212327. https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.12327.","journal-title":"JAMA Netw Open"},{"key":"5202_CR36","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.ejca.2023.03.014","volume":"187","author":"D Schadendorf","year":"2023","unstructured":"Schadendorf D, Tawbi H, Lipson EJ, et al. Health-related quality of life with nivolumab plus relatlimab versus nivolumab monotherapy in patients with previously untreated unresectable or metastatic melanoma: RELATIVITY-047 trial. Eur J Cancer. 2023;187:164\u201373. https:\/\/doi.org\/10.1016\/j.ejca.2023.03.014.","journal-title":"Eur J Cancer"},{"key":"5202_CR37","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.24.01125","author":"JC Moser","year":"2024","unstructured":"Moser JC, Shah D, Dronca RS, et al. Indirect comparison of nivolumab plus relatlimab versus nivolumab plus ipilimumab in advanced melanoma. J Clin Oncol. 2024. https:\/\/doi.org\/10.1200\/JCO.24.01125.","journal-title":"J Clin Oncol"},{"key":"5202_CR38","doi-asserted-by":"publisher","DOI":"10.59449\/joco.2025.02.15","author":"Y Saito","year":"2025","unstructured":"Saito Y, Miller D, Brownell I. Comparing first-line immunotherapy in advanced melanoma: no clear winner? J Cutan Oncol. 2025. https:\/\/doi.org\/10.59449\/joco.2025.02.15.","journal-title":"J Cutan Oncol"},{"issue":"17","key":"5202_CR39","doi-asserted-by":"publisher","first-page":"3253","DOI":"10.1158\/1078-0432.CCR-23-1194","volume":"29","author":"RC Augustin","year":"2023","unstructured":"Augustin RC, Luke JJ. PD-1 monotherapy reigns supreme in adjuvant melanoma\u2026But for how long? Clin Cancer Res. 2023;29(17):3253\u20135. https:\/\/doi.org\/10.1158\/1078-0432.CCR-23-1194.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"5202_CR40","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.pathol.2021.11.002","volume":"54","author":"RA Scolyer","year":"2022","unstructured":"Scolyer RA, Atkinson V, Gyorki DE, et al. BRAF mutation testing for patients diagnosed with stage III or stage IV melanoma: practical guidance for the Australian setting. Pathology. 2022;54(1):6\u201319. https:\/\/doi.org\/10.1016\/j.pathol.2021.11.002.","journal-title":"Pathology"},{"issue":"1","key":"5202_CR41","doi-asserted-by":"publisher","DOI":"10.1007\/s12672-024-01702-w","volume":"15","author":"C Acar","year":"2024","unstructured":"Acar C, Y\u00fcksel H\u00c7, \u015eahin G, et al. Efficacy and prognostic factors of anti-PD1 and nivolumab-ipilimumab therapy in advanced melanoma patients resistant to prior ICI treatment. Discover Oncol. 2024;15(1):813. https:\/\/doi.org\/10.1007\/s12672-024-01702-w.","journal-title":"Discover Oncol"},{"issue":"6","key":"5202_CR42","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1016\/S1470-2045(21)00097-8","volume":"22","author":"I Pires da Silva","year":"2021","unstructured":"Pires da Silva I, Ahmed T, Reijers ILM, et al. Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study. Lancet Oncol. 2021;22(6):836\u201347. https:\/\/doi.org\/10.1016\/S1470-2045(21)00097-8.","journal-title":"Lancet Oncol"},{"issue":"9","key":"5202_CR43","doi-asserted-by":"publisher","first-page":"2278","DOI":"10.1038\/s41591-023-02498-y","volume":"29","author":"A VanderWalde","year":"2023","unstructured":"VanderWalde A, Bellasea SL, Kendra KL, et al. Ipilimumab with or without nivolumab in PD-1 or PD-L1 blockade refractory metastatic melanoma: a randomized phase 2 trial. Nat Med. 2023;29(9):2278\u201385. https:\/\/doi.org\/10.1038\/s41591-023-02498-y.","journal-title":"Nat Med"},{"issue":"1","key":"5202_CR44","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1189\/jlb.1212621","volume":"94","author":"AM Intlekofer","year":"2013","unstructured":"Intlekofer AM, Thompson CB. At the bench: preclinical rationale for CTLA-4 and PD-1 blockade as cancer immunotherapy. J Leukoc Biol. 2013;94(1):25\u201339. https:\/\/doi.org\/10.1189\/jlb.1212621.","journal-title":"J Leukoc Biol"},{"issue":"1","key":"5202_CR45","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15010031","volume":"15","author":"B Gautron Moura","year":"2022","unstructured":"Gautron Moura B, Gerard CL, Testart N, et al. Estimated costs of the ipilimumab-nivolumab therapy and related adverse events in metastatic melanoma. Cancers (Basel). 2022;15(1): 31. https:\/\/doi.org\/10.3390\/cancers15010031.","journal-title":"Cancers (Basel)"},{"issue":"7","key":"5202_CR46","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgph.0003418","volume":"4","author":"S Malhotra","year":"2024","unstructured":"Malhotra S, Cameron AI, Gotham D, et al. Novel approaches to enable equitable access to monoclonal antibodies in low- and middle-income countries. PLOS Glob Public Health. 2024;4(7): e0003418. https:\/\/doi.org\/10.1371\/journal.pgph.0003418.","journal-title":"PLOS Glob Public Health"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-026-05202-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-026-05202-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-026-05202-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:05:19Z","timestamp":1784073919000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-026-05202-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,21]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["5202"],"URL":"https:\/\/doi.org\/10.1007\/s12672-026-05202-x","relation":{},"ISSN":["2730-6011"],"issn-type":[{"value":"2730-6011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,21]]},"assertion":[{"value":"13 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1025"}}